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could influence the cost and quality of life of patients. To assess the cost-effectiveness 
of adding a PPI compared to no PPI co-treatment in older patients LDASA. Methods: 
A cost-effectiveness study was conducted with a Markov model for PPI co-medication 
(intervention) compared to no PPI co-medication (usual care) in LDASA users. The 
base case analysis was performed for patients of 70 years old. The models addressed 
chronic LDASA use of five years. Incremental cost-utility ratio’s (ICURs), expressed as 
costs per QALY gained, were calculated for different age categories (60 up to 80 years) 
accounting for different risk rates for side effects from LDASA or PPI use. These side 
effects included gastrointestinal bleeding, dyspepsia, pneumonia and hip fractures. 
Finally, a budget impact analysis was performed to assess the health care expen-
ditures to add PPIs in all current patients using LDASA above the age of 60 years 
in the Netherlands. Results: Adding a PPI to LDASA, compared to not adding a 
PPI, resulted in incremental costs of € 71,84 and incremental effects of 0,006 QALY’s 
and an ICUR of € 11,491.53/QALY gained for the base case analysis. The ICUR for 60- 
and 80-year old patients was € 11,491.53/QALY and € 53,860.85/QALY, respectively. 
The total budget impact of adding a PPI to current LDASA users (≥ 60 years) was 
€ 174,475,296. ConClusions: Adding a PPI to LDASA users may be a cost-effective 
approach in patients from 60 up to 80 years old. However, with increasing age the costs 
became higher and the effects lower, due to higher risks of the different side effects.
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objeCtives: The objective of this study was to analyze the cost-effectiveness of bio-
logics compared to conventional disease-modifying antirheumatic drugs (cDMARDs) 
for the treatment of rheumatoid arthritis (RA) using real world data from Finnish 
national registers. Methods: RA patients starting their first biologics 2007 - 2011 and 
comparator patients using cDMARDs during the same time period were obtained from 
the National register of biologic treatments in Finland (ROB-FIN) and from the Central 
Finland Central Hospital (CFCH) patient records. Medication changes were allowed 
and patients were followed up to two years. Propensity score matching was applied 
to adjust difference between biologics and cDMARD users. Effectiveness in quality 
adjusted life years (QALY) was based on ROB-FIN and CFCH patient records while the 
direct costs of medication and health care utilization were obtained from relevant 
Finnish national registers. Mean costs and effectiveness as well as 95% confidence 
intervals were calculated using bootstrap resampling approach. Both the costs and 
effectiveness were discounted at 3%. Results: Of 1487 patients RA patients meeting 
study inclusion criteria, 608 biologic users and 300 cDMARD users were included in 
analyses after propensity score matching. Mean follow up times were 463 and 538 
days for biologic users and cDMARD users, respectively. Mean costs for biologics and 
cDMARDs were 57,900 € (CI 95% 54,800 - 60,900 € ) and 21,900 € (CI 95% 17,300 - 26,500 
€ ), while mean effectiveness was 1.2064 (CI 95% 1.1756 -1.2373) and 1.2066 QALYs 
(CI 95% 1.1751 -1.2381), respectively. ConClusions: The high cost of biologics and 
the small, non-significant difference in effectiveness for the advantage of cDMARDs 
resulted in cDMARDs being dominant treatment. However, regardless the propensity 
score matching, latent confounders may introduce bias to the results.
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objeCtives: To evaluate the relative health gains and costs of secondary preven-
tion of fractures with generic alendronate, risedronate, denosumab and zoledronic 
acid. Methods: We evaluated the cost-effectiveness based on a previously devel-
oped decision analytic fracture model. The model synthesizes available data on the 
epidemiology of fractures and related mortality, need for long-term care and home 
based assistance. The model is set up as an individual level Markov model and out-
puts include number of quality adjusted life years (QALYs) and costs. Effectiveness 
data were gathered from a recent systematic review and costs were collected from 
publicly available sources. We preformed analyses for women 85 years old with a 
previous hip fracture. In this first preliminary analysis, we assumed full compliance 
and lifelong treatment. Results: Zoledronic acid was the most effective alternative, 
followed by denosumab, risedronate, generic alendronate and no treatment, yield-
ing respectively 4.7661, 4.7640, 4.6715, 4.1581 and 3.8915 QALYs. In terms of costs, 
generic alendronate was the best options, being less costly than no secondary pre-
vention. In terms of cost-effectiveness, no treatment, denosumab and risedronate 
were excluded based on dominance, seeing that alendronate was more effective and 
less costly than no treatment, and zoledronic acid was more effective and less costly 
than both denosumab and risedronate. Compared to alendronate, zoledronic acid 
yields an incremental cost-effectiveness ratio of $48,832 per QALY. ConClusions: 
All options are effective compared to no treatment. In terms of comparative effec-
tiveness and cost-effectiveness, our analysis indicates that zoledronic acid is the 
optimal strategy for secondary prevention, assuming a cost-effectiveness threshold 
of $50,000 per QALY gained.
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Bootstrap analyses with 1000 replications were used. Results: 180 patients were 
included; 121 were allocated to the dose optimisation strategy, 59 to control. The 
dose optimisation strategy resulted in mean cost savings of -€ 12,280 (95 percentile 
-€ 10,502; -€ 14,104) per patient. There is a 84% chance that the dose optimisation 
strategy results in QALY loss with a mean loss of -0.02 (-0.07; 0.02). When using a 
willingness to pay (WTP) level of € 80,000 per QALY, the mean iNMB is € 10,467 (€ 6,553; 
€ 14,037) per patient per 18 months. Sensitivity analyses using prices -30% and -50% 
still resulted in a cost effective strategy. ConClusions: Disease activity guided 
dose optimisation of TNFi results in considerable cost savings with no relevant loss 
of quality of life. When the minimal QALY loss is compensated with the upper limit 
of what society is willing to pay in Netherlands, the net savings are still high, even 
when future price drops are taken into account.
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objeCtives: To determine the cost-utility of ustekinumab (UST) administered sub-
cutaneously every 12 weeks (after induction), compared with adalimumab (ADA) 
administered subcutaneously every two weeks, and infliximab (INF), administered 
intravenously every eight weeks (after induction) in treating moderate-to-severe 
psoriatic arthritis (PsA) in Russia. Methods: A Markov model was developed with 
expert panel input. Biologic-naïve patients entered the model, progressing over 
the 10-year analytic horizon in annual cycles according to observed transition 
probabilities. Six sequences of 1st line/2nd line/3rd line treatment were simulated: 
UST/ADA/INF, UST/INF/ADA, ADA/UST/INF, ADA/INF/UST, INF/ADA/UST, and INF/
UST/ADA, with best supportive care used when all three failed. Retention rates 
were extracted from PSOLAR database. Utilities for UST successes/failures were 
derived directly from PSUMMIT-1&2 trials using the HAQ-DI mapped to EQ-5D using 
Rodgers’ equation; INF and ADA utilities were obtained from Yang’s NICE submission 
(2012). Costs from the Russian Ministry of Health perspective were obtained from 
standard lists, converted to 2014 euros and discounted at 5%, as per Russian phar-
macoeconomic guidelines. Robustness was tested using one-way and probabilistic 
sensitivity analyses with 10,000 iterations. Results: Respective expected costs 
were 132,730€ , 135,187€ , 135,413€ , 138,412€ , 151,457€ and 165,636€ ; respective QALYs 
were 6.598, 6.673, 6.656, 6.690, 6.760 and 6.832. UST/ADA/INF had the lowest cost. 
UST/INF/ADA and ADA/INF/UST were dominated. ICERs for the remaining strate-
gies were ADA/UST/INF:32,568€ , INF/ADA/UST:187,113€ and INF/UST/ADA:197,929€ . 
Despite adding a few more QALYs, all ICERs fell well above the 2014 NICE thresh-
old for cost-effectiveness (24,800€ ). Overall, the model was sensitive to changes in 
drug prices. Starting with UST potentially saves 41.7€ million over starting with 
ADA and 318€ million over starting with INF in the 17,000 patients eligible for bio-
logicals. ConClusions: In Russia, the cost-effective approach for patients with 
moderate-to-severe PsA that failed DMARDs is to initiate biologic therapy with UST, 
use ADA as second line and INF as third line.
PMS81
toCiliZuMaB in MEthotrExatE-naïvE rhEuMatoid arthritiS – a CoSt-
utility ModEl for SlovaKia
Chang S1, Sawyer L1, Dejonckheere F2, Grichova L3, Diamantopoulos A1
1Symmetron Limited, Elstree, UK, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3Roche 
Slovensko, s.r.o., Bratislava, Slovak Republic
objeCtives: To assess the cost-utility of Tocilizumab (TCZ) in the treatment 
of methotrexate (MTX)-naïve adults with active rheumatoid arthritis (RA) in 
Slovakia. Methods: A decision tree model was developed to reflect the early 
management of MTX-naïve adult RA patients in Slovakia. Efficacy, DAS28 remis-
sion, for each treatment in the model was derived from a network meta-analysis 
(NMA) of randomised controlled trials (RCTs) [Sawyer et al. 2015]. Benefits were 
measured in Quality Adjusted Life years (QALYs) derived by mapping DAS28 scores 
onto EQ-5D utility weights. The analysis was conducted from the third-party payer 
perspective, and included direct medical costs (drugs, administration, monitoring). 
The time horizon is one year, in line with the maximum follow-up period from 
RCTs. Incremental costs and QALYs associated with TCZ±MTX were compared to 
anti-tumour necrosis factors (TNFs), including adalimumab (ADA), etanercept (ETN) 
and infliximab (IFX), within their licensed indications. Each treatment was also 
compared to MTX alone. Variables related to efficacy, cost and utility were tested in 
the sensitivity analysis. Results: TCZ±MTX had a lower incremental cost-effec-
tiveness ratio (ICER) than other TNFs ±MTX when compared to MTX alone in base 
case. When compared head-to-head with TNFs, TCZ was cost-effective, with ICERs 
range from € 6,500 to € 16,000 per QALY gained in monotherapy and from € 10,000 
to € 24,000 per QALY gained in combination therapy. Furthermore, TCZ+MTX domi-
nated IFX+MTX. The full incremental analysis showed that TCZ±MTX was the next 
most cost-effective strategy after MTX. Results of the sensitivity analysis showed 
the efficacy variables and the assumption on the utility mapping formula have an 
impact on the ICERs. ConClusions: The results suggest TCZ is a cost-effective 
alternative to the approved and reimbursed TNFs, used either as monotherapy or in 
combination with MTX in the treatment of MTX-naïve adult RA patients in Slovakia.
PMS82
CoSt-EffECtivEnESS of Proton PuMP inhiBitor initiation aiMEd to 
PrEvEnt uPPEr gaStrointEStinal toxiCity in PatiEntS uSing low-doSE 
aCEtylSaliCyliC aCid
Sluiter R1, Chau SH2, Kievit W1, Teichert M1, Hugtenburg J2
1Radboudumc, Nijmegen, The Netherlands, 2VU university medical center, Amsterdam, The 
Netherlands
objeCtives: Proton pump inhibitors (PPI) are not always added to the treatment of 
low dose acetylsalicylic acid (LDASA), but is proven to be effective in preventing upper 
gastrointestinal toxicity. However, PPI’s may also have additional side effects that 
